Summary of Neurocrine Biosciences Conference Call Company Overview - **Company**: Neurocrine Biosciences (NasdaqGS:NBIX) - **Date of Conference**: March 17, 2026 - **Key Speakers**: Kyle Gano (CEO), Todd Tushla (Head of IR) Key Points 1. Financial Performance - **2025 Revenue**: Approximately $2.8 billion, representing a **22% year-over-year growth** [4] - **Ingrezza Revenue**: $2.51 billion in 2025, with a **9% year-over-year growth** and double-digit volume growth [5] - **2026 Revenue Guidance**: Expected to be between **$2.7 billion and $2.8 billion** [11] - **Price Trends**: Anticipated **4%-5% price decline** year-over-year for Ingrezza due to expanded access [12] 2. Product Performance - **Ingrezza**: - Eighth year of commercialization with strong sales performance. - Focus on expanding prescriber base, targeting **30% new prescribers** [6] - Anticipated strong year with **double-digit volume growth** [31] - **CRENESSITY**: - First year of commercial sales generated **$300 million** in revenue, capturing **10% of the CH market** [7] - High reimbursement rates with **80% of dispensed scripts reimbursed** [7] - Focus on educational support for physicians and patients to change the standard of care [8] 3. Pipeline and Future Developments - **Phase 3 Trials**: - Osavampator and direclidine expected to deliver data in **2027** [8] - NBI-570 (M1M4 dual agonist) in schizophrenia and NBI-890 (next-generation VMAT2 inhibitor) in phase 2 trials [9][10] - **Next-Generation VMAT2 Program**: - Focus on long-acting injectable formulations to improve patient compliance [72] - **CRF1 Antagonist (NBIP-1435)**: - In phase 1, moving to phase 2/3 later this year, offering a long-acting injectable option [80] 4. Market Dynamics and Competitive Landscape - **Market Access**: - 70% of TD and HD patients under existing contracts, providing a strong market position [36] - **Competitor Analysis**: - Teva's MFP implementation in 2027 and 2028 may impact pricing strategies [36] - **Regulatory Environment**: - Ongoing negotiations with Medicare plans for 2027, with expectations for adjacent MFP products [37] 5. Strategic Focus - **Execution and Data Delivery**: - Emphasis on executing current strategies and delivering data across phase 2 and phase 3 programs in 2027 [10] - **Sustainable Innovation**: - Commitment to a diversified pipeline and innovation engine to support long-term growth [86] 6. Additional Insights - **Patient Compliance**: - Importance of addressing patient reauthorization processes and maintaining access to prescriptions [44] - **Market Sensitivity**: - Anticipation of emotional responses to new patient start forms, with a focus on consistent growth trends [42] Conclusion Neurocrine Biosciences is positioned for continued growth with a strong financial profile, a diversified product portfolio, and a robust pipeline of upcoming clinical data. The company is focused on execution and market access strategies to navigate competitive pressures and regulatory challenges while aiming to enhance patient care through innovative therapies.